O’Brien, Hugh http://orcid.org/0000-0002-6829-5306
Salm, Max
Morton, Laura T.
Szukszto, Maciej http://orcid.org/0000-0002-0463-652X
O’Farrell, Felix
Boulton, Charlotte
Becker, Pablo D.
Samuels, Yardena http://orcid.org/0000-0002-3349-7266
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Mansour, Marc R. http://orcid.org/0000-0001-6835-3791
Reker Hadrup, Sine
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
EC | Horizon 2020 Framework Programme (964998)
Article History
First Online: 15 December 2023
Change Date: 15 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-024-00767-4
Competing interests
: S.A.Q. is co-founder and chief scientific officer and own shares in Achilles Therapeutics. C.S. acknowledges grants from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously Archer Dx Inc., a collaboration in minimal residual disease sequencing technologies), Ono Pharmaceutical and Personalis. He is chief investigator for the AZ MeRmaiD 1 and 2 clinical trials and is the steering committee chair. He is also co-chief investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s scientific advisory board (SAB). He receives consultant fees from Achilles Therapeutics (also an SAB member); Bicycle Therapeutics (also an SAB member); Genentech; Medicxi; the China Innovation Centre of Roche (CICoR), formerly Roche Innovation Centre Shanghai; Metabomed (until July 2022); Relay Therapeutics; and the Sarah Cannon Research Institute. C.S has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Illumina, MSD, Novartis, Pfizer and Roche-Ventana; previously held stock options in Apogen Biotechnologies and GRAIL; currently has stock options in Epic Bioscience and Bicycle Therapeutics; and has stock options and is co-founder of Achilles Therapeutics. S.R.H. is the cofounder of PokeAcell and is co-inventor of licensed patents related to T cell detection. H.O’B., M.S., L.M. and F.O’F. are employees of Achilles Therapeutics.